vTv Therapeutics/$VTVT

1D1W1MYTD1Y5YMAX

About vTv Therapeutics

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Ticker
$VTVT
Sector
Health
Primary listing
NASDAQ
Employees
26
Headquarters
High Point, United States
Website
vtvtherapeutics.com

vTv Therapeutics Metrics

BasicAdvanced
$386M
-
-$0.42
0.29
-

What the Analysts think about vTv Therapeutics

Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
Analyst projections of the future price of vTv Therapeutics stock.

Bulls say / Bears say

CATT1 is nearing a major value inflection point: vTv expects to finish Phase 3 enrolment in the third quarter of 2026, with top-line data expected in 2027. That gives investors a clear, relatively near-term catalyst. (GlobeNewswire, Quartr)
The latest conference summary says earlier Phase 2 work showed HbA1c lowering alongside about a 50% reduction in hypoglycaemia. If Phase 3 confirms this benefit, cadisegliatin could offer a differentiated oral adjunct to insulin in a setting with a major unmet need. (Quartr)
The HPP737 licence amendment delivered a $20 million upfront payment without issuing shares, with potential development and sales milestones of up to about $115 million plus royalties. This gives vTv additional non-dilutive funding while it concentrates resources on cadisegliatin. (GlobeNewswire, StockTitan)
CATT1 enrolment initially progressed more slowly than expected, forcing vTv to expand sites and increase engagement efforts. Although the company now expects completion in the third quarter, any further delay could push the data catalyst beyond 2027 and increase costs. (Last10K, Quartr)
Cadisegliatin remains investigational, so its safety and efficacy are not established and regulatory approval is not assured. CATT1 must deliver the required reduction in hypoglycaemia while preserving glycaemic control; failure would leave vTv with a highly concentrated clinical investment at risk. (GlobeNewswire, Quartr)
vTv has no product revenue, has generated net losses in every year of its existence and reported an accumulated deficit of $315.6 million at 30 June 2026. Management expects current cash to last only through the CATT1 top-line readout and says further development will require additional financing, creating dilution or funding risk. (Last10K, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.

vTv Therapeutics Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

vTv Therapeutics Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.